| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Neurobiology Department,*
University Medical
School, Newcastle upon Tyne, United Kingdom;
Généthon,
Évry, France;
Institut de Myologie,
Hôpital de la
Salpêtrière, Paris, France; Abteilung
Neuropädiatrie,§
Kinderklinik,
Humboldt-Universität, Berlin, Germany; Unitat de Genètica
Molecular,¶ Hospital de la Santa Creu i
Sant Pau, Barcelona, Spain; and Unitat de Patologia
Neuromuscular,||
Servei de Neurologia, Hospital Sant Joan
de Déu, Barcelona, Spain
Monoclonal antibodies were raised to two regions of calpain 3 (muscle-specific calcium-activated neutral protease), which is the product of the gene that is defective in limb-girdle muscular dystrophy type 2A. The antibodies produced characteristic patterns of bands on Western blots: normal calpain 3 protein was represented by bands at 94 kd, plus additional fragments at ~60 or 30 kd, according to the antibody used. Specificity was confirmed by the loss of all bands in patients with null gene mutations. The "normal" profile of bands was observed in muscle from 33 control subjects and 70 disease-control patients. Calpain 3 protein was found to be extremely stable in fresh human muscle, with full-size protein being detected 8 hours after the muscle had been removed. Blots of muscle from nine limb-girdle muscular dystrophy type 2A patients with defined mutations showed variation in protein expression, with seven showing a clear reduction in the abundance of protein detected. No simple relationship was found between the abundance and clinical severity. Two patients showed normal expression of the full-size 94 kd band accompanied by a clear reduction in the smaller fragments. This pattern was also observed in one patient with an undefined form of limb-girdle dystrophy. These results indicate that immunodiagnosis is feasible, but caution will need to be exercised with the interpretation of near-normal protein profiles.
This article has been cited by other articles:
 |
|
 |
|
  E. J. Groen, R. Charlton, R. Barresi, L. V. Anderson, M. Eagle, J. Hudson, M. S. Koref, V. Straub, and K. M. D. Bushby Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A Brain, December 1, 2007; 130(12): 3237 - 3249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Fanin, L Nardetto, A C Nascimbeni, E Tasca, M Spinazzi, R Padoan, and C Angelini Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A J. Med. Genet., October 1, 2007; 44(10): 609 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nguyen, G. Bassez, M. Krahn, R. Bernard, P. Laforet, V. Labelle, J. A. Urtizberea, D. Figarella-Branger, N. Romero, S. Attarian, et al. Phenotypic Study in 40 Patients With Dysferlin Gene Mutations: High Frequency of Atypical Phenotypes Arch Neurol, August 1, 2007; 64(8): 1176 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Fanin, A C Nascimbeni, and C Angelini Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations J. Med. Genet., January 1, 2007; 44(1): 38 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Geesink, S. Kuchay, A. H. Chishti, and M. Koohmaraie {micro}-Calpain is essential for postmortem proteolysis of muscle proteins J Anim Sci, October 1, 2006; 84(10): 2834 - 2840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ono, F. Torii, K. Ojima, N. Doi, K. Yoshioka, Y. Kawabata, D. Labeit, S. Labeit, K. Suzuki, K. Abe, et al. Suppressed Disassembly of Autolyzing p94/CAPN3 by N2A Connectin/Titin in a Genetic Reporter System J. Biol. Chem., July 7, 2006; 281(27): 18519 - 18531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Murphy, R. J. Snow, and G. D. Lamb {micro}-Calpain and calpain-3 are not autolyzed with exhaustive exercise in humans Am J Physiol Cell Physiol, January 1, 2006; 290(1): C116 - C122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Geesink, R. G. Taylor, and M. Koohmaraie Calpain 3/p94 is not involved in postmortem proteolysis J Anim Sci, July 1, 2005; 83(7): 1646 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zatz and A. Starling Calpains and Disease N. Engl. J. Med., June 9, 2005; 352(23): 2413 - 2423. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Verburg, R. M. Murphy, D. G. Stephenson, and G. D. Lamb Disruption of excitation-contraction coupling and titin by endogenous Ca2+-activated proteases in toad muscle fibres J. Physiol., May 1, 2005; 564(3): 775 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Saenz, F. Leturcq, A. M. Cobo, J. J. Poza, X. Ferrer, D. Otaegui, P. Camano, M. Urtasun, J. Vilchez, E. Gutierrez-Rivas, et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene Brain, April 1, 2005; 128(4): 732 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fanin, A. C. Nascimbeni, L. Fulizio, C. P. Trevisan, M. Meznaric-Petrusa, and C. Angelini Loss of Calpain-3 Autocatalytic Activity in LGMD2A Patients with Normal Protein Expression Am. J. Pathol., November 1, 2003; 163(5): 1929 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Vainzof, F de Paula, A M Tsanaclis, and M Zatz The effect of calpain 3 deficiency on the pattern of muscle degeneration in the earliest stages of LGMD2A J. Clin. Pathol., August 1, 2003; 56(8): 624 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. GOLL, V. F. THOMPSON, H. LI, W. WEI, and J. CONG The Calpain System Physiol Rev, July 1, 2003; 83(3): 731 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Spencer, J. R. Guyon, H. Sorimachi, A. Potts, I. Richard, M. Herasse, J. Chamberlain, I. Dalkilic, L. M. Kunkel, and J. S. Beckmann Stable expression of calpain 3 from a muscle transgene in vivo: Immature muscle in transgenic mice suggests a role for calpain 3 in muscle maturation PNAS, June 25, 2002; 99(13): 8874 - 8879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Haravuori, A. Vihola, V. Straub, M. Auranen, I. Richard, S. Marchand, T. Voit, S. Labeit, H. Somer, L. Peltonen, et al. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: Titin is the candidate gene Neurology, April 10, 2001; 56(7): 869 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fanin, E. Pegoraro, C. Matsuda-Asada, R.H. Brown Jr., and C. Angelini Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy Neurology, March 13, 2001; 56(5): 660 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Talim, A. Ognibene, E. Mattioli, I. Richard, L.V.B. Anderson, and L. Merlini Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A Neurology, March 13, 2001; 56(5): 692 - 693. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tagawa, C. Taya, Y. Hayashi, M. Nakagawa, Y. Ono, R. Fukuda, H. Karasuyama, N. Toyama-Sorimachi, Y. Katsui, S. Hata, et al. Myopathy phenotype of transgenic mice expressing active site-mutated inactive p94 skeletal muscle-specific calpain, the gene product responsible for limb girdle muscular dystrophy type 2A Hum. Mol. Genet., May 22, 2000; 9(9): 1393 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. D. Bushby The limb-girdle muscular dystrophies--multiple genes,multiple mechanisms Hum. Mol. Genet., September 1, 1999; 8(10): 1875 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. D. Bushby Making sense of the limb-girdle muscular dystrophies Brain, August 1, 1999; 122(8): 1403 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. B. Anderson and K. Davison Multiplex Western Blotting System for the Analysis of Muscular Dystrophy Proteins Am. J. Pathol., April 1, 1999; 154(4): 1017 - 1022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-L. Chou, C. Angelini, D. Daentl, C. Garcia, C. Greco, I. Hausmanowa-Petrusewicz, A. Fidzianska, H. Wessel, and E. P. Hoffman Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population Neurology, March 1, 1999; 52(5): 1015 - 1015. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
